PROTHENA CORP PUBLIC LTD CO
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. OTHER INFORMATION
On February 26, 2024, Carol D. Karp, Chief Regulatory Officer, adopted a Rule 10b5-1 trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 105,000 shares of the Company’s ordinary shares until June 3, 2025. However, this plan wasterminated on March 29, 2024. On March 29, 2024, Ms. Karp adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 105,000 shares of the Company’s ordinary shares until June 3, 2025.
On February 26, 2024, Tran B. Nguyen, Chief Strategy Officer and Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 510,150 shares of the Company’s ordinary shares until May 15, 2025.
On March 13, 2024, Gene G. Kinney, President and Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 141,599 shares of the Company’s ordinary shares until June 15, 2025.
On March 21, 2024, Richard T. Collier, director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 18,229 shares of the Company’s ordinary shares until May 22, 2025.
On March 21, 2024, Shane M. Cooke, director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 18,229 shares of the Company’s ordinary shares until May 22, 2025.
On March 21, 2024, Hideki Garren, Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 90,000 shares of the Company’s ordinary shares until June 30, 2025.
On March 26, 2024, Lars G. Ekman, director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 18,229 shares of the Company’s ordinary shares until May 22, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.